Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27947132 | 0.78 | HSP90AA1 (0.31) | MEN1KMT2A | |
| SCHEMBL9869049 | 0.75 | MAPK1 (0.39) | KDM4EGAAKMT2AALDH1A1LMNA | |
| SCHEMBL31011779 | 0.73 | NPC1 (0.50) | KDM4EMEN1GAAKMT2AALDH1A1 | |
| SCHEMBL2413590 | 0.73 | NPC1 (0.50) | KDM4EMEN1GAAKMT2AALDH1A1 | |
| SCHEMBL7196085 | 0.73 | — | — | |
| SCHEMBL27651050 | 0.69 | MAPT (0.40) | KDM4EMEN1GLAKMT2AALDH1A1 | |
| SCHEMBL4772249 | 0.69 | RAB9A (0.48) | KDM4EMEN1GAAKMT2AALDH1A1 | |
| SCHEMBL7013482 | 0.69 | — | — | |
| SCHEMBL27761355 | 0.67 | — | — | |
| SCHEMBL57064 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063463-A | Preparation method of entecavir | 苏州科技大学 | 2024-05-24 | — | — | CN | disclosed |
| US-10239859-B2 | Nitrogen-containing heterocycles as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-03-26 | — | — | US | disclosed |
| US-20180201600-A1 | NITROGEN-CONTAINING HETEROCYCLES AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-07-19 | — | — | US | disclosed |
| EP-3319943-A1 | NITROGENOUS HETEROCYCLES AS A PESTICIDE | Bayer CropScience Aktiengesellschaft (DE) | 2018-05-16 | — | — | EP | disclosed |
| EP-1689493-A4 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1730137-A1 | HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | Bristol-Myers Squibb Company (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1689493-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Pharma Company (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005095383-A1 | HETEROCYCLIC CGRP ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005065779-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1539766-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2003104236-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
| US-4116674-A | Process of severely damaging or killing unwanted plants with pyrimidine compounds | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-09-26 | — | — | US | disclosed |
| US-3950524-A | Hypoglycemic benzenesulfonamido pyrimidines | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201600-A1 | NITROGEN-CONTAINING HETEROCYCLES AS PESTICIDES | DDT, DNPH1, PTMS | KDM4E 1522/4885MEN1 1996/4885USP2 1504/4885 |
| US-10239859-B2 | Nitrogen-containing heterocycles as pesticides | DDT, DNPH1, PTMS | KDM4E 1522/4885MEN1 1996/4885USP2 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.